Study of rilvegostomig for advanced solid tumors
Part of Cancer clinical trials.
This trial tests an experimental drug called rilvegostomig, given as a shot under the skin, for people with advanced solid tumors that have spread or can't be removed and have already had standard treatments. The study checks how the body processes the drug and its safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor that has spread or can't be removed with surgery.
- You have already received at least one type of cancer treatment for your disease.
- Your doctor thinks immunotherapy would be appropriate for you.
- You are able to care for yourself (ECOG score 0 or 1) and expected to live at least 12 weeks.
- Your organs and bone marrow are working well enough, and you weigh at least 30 kg (about 66 pounds).
- You do not have serious uncontrolled medical conditions, active infections, or autoimmune disorders needing steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug that may help people with advanced solid tumors, including liver, stomach, and brain cancers. It is for patients whose cancer has not responded to standard treatments or who cannot have them. The study aims to find the right dose and check safety and effectiveness.
This trial tests a new immunotherapy drug called rilvegostomig combined with standard chemotherapy to see if it can help people with advanced stomach or gastroesophageal junction cancer. It may boost the body's immune system to fight the cancer better.
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer that has high levels of PD-L1 protein. The goal is to see which drug works better as a first treatment before any other cancer therapy.
This trial tests a new immunotherapy drug, rilvegostomig, against the standard pembrolizumab, both given with chemotherapy, as a first treatment for advanced non-squamous non-small cell lung cancer (NSCLC) that cannot be cured with surgery or radiation. It is for people whose tumors have high PD-L1 levels and do not have certain genetic mutations.
This trial tests new drug combinations for people with advanced or metastatic non-small cell lung cancer (NSCLC). Depending on your PD-L1 level and genetic profile, you may be placed in one of three groups to see if these combinations help shrink or control your tumor.
This study tests a new drug (rilvegostomig) alone or with chemotherapy or another drug (ramucirumab) for advanced non-small cell lung cancer that has spread. It aims to see if these combinations work better than standard treatments.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.